ArticleHealth economics review2015

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.

Rainel Sánchez-de la Rosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.